adult-onset Still's disease: adult-onset Still disease (AOSD) is a rare inflammatory multisystem disorder characterized clinically by fever of unknown origin, arthralgia or arthritis, hyperleucocytosis, and typical skin rash.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
172 |
4. Check minimum number of eventsNone |
172 |
5. Include endpointsNone |
172 |
6. Filter based on genotype QC (FinnGen only) |
149 |
Control definitions (FinnGen only)
- Control exclude
- ILD_SYST_AUTO_DISEASES
Extra metadata
- First used in FinnGen datafreeze
- DF5
- Parent code in ICD-10
- M06
- Name in latin
- Arthritis rheumatoides seronegativa
Similar endpoints
↥List of similar endpoints to
Adult-onset Still disease
based on the number of shared cases.
Similar with more cases:
- Other (seronegative) rheumatoid arthritis, wide
- Rheumatoid arthritis
- Rheumatoid arthritis, including avohilmo
- Polyarthropathies
- Autoimmune diseases related-to ILD
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 695 | 385 | 303 |
| Only index persons | 637 | 353 | 284 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 49.30 | 49.81 | 48.68 |
| Only index persons | 47.00 | 47.43 | 46.47 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 149 | 93 | 56 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 45.45 | 43.78 | 48.21 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 159
- Matched controls
- 1590
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M06.1
ICD-10 Finland
Adult-onset Still disease
+∞
229.9
159
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
64.1
160.6
112
57
L01BA01
ATC
methotrexate; systemic
86.3
114.9
63
12
L04AX03
ATC
methotrexate; systemic
33.6
114.0
93
64
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
58.6
83.7
49
12
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
27.5
81.8
64
38
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
25.6
72.2
57
34
P01BA02
ATC
hydroxychloroquine; oral
19.1
70.5
68
60
A07EC01
ATC
sulfasalazine; oral, rectal
23.5
67.4
55
35
R50.9
ICD-10 Finland
Fever, unspecified
11.9
57.0
90
157
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
134.7
52.8
54
6
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
17.5
49.0
45
35
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
116.7
47.0
49
6
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
9.9
46.0
111
300
M05BA04
ATC
alendronic acid; oral
15.0
45.5
46
42
H02AB06
ATC
prednisolone; systemic
16.2
42.8
141
518
M13.9
ICD-10 Finland
Arthritis, unspecified
11.3
34.8
42
49
H02AB07
ATC
prednisone; oral
8.1
31.2
52
90
L04AC03
ATC
anakinra; parenteral
+∞
27.9
26
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
9.0
25.8
36
50
M08.2
ICD-10 Finland
Juvenile arthritis with systemic onset
+∞
25.7
24
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.8
25.0
111
456
L88
ICPC
Rheumatoid/seropositive arthritis
25.1
24.3
34
17
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
28.2
23.7
32
14
L04AA13
ATC
[U] leflunomide
44.0
21.5
26
7
L04AX01
ATC
azathioprine; systemic
34.1
20.4
26
9
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.5
20.3
39
76
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.7
20.1
46
106
L04AB04
ATC
adalimumab; parenteral
113.6
19.0
20
*
L04AA01
ATC
[U] ciclosporin
56.8
17.4
20
*
252, ,
Kela drug reimbursment
+∞
17.0
16
*
NF1AA
NOMESCO Finland
Hip X-ray examination
6.7
16.5
29
51
3053, ,
Kela drug reimbursment
+∞
15.9
15
*
ZX120
NOMESCO Finland
Intravenous
5.8
15.0
31
64
M08.0
ICD-10 Finland
Juvenile rheumatoid arthritis
+∞
14.8
14
*
L04AD01
ATC
ciclosporin; systemic
33.5
14.2
18
6
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.8
13.8
36
91
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
5.2
13.3
31
71
NH3DA
NOMESCO Finland
Bilateral foot X-ray examination
22.3
12.8
18
9
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
18.3
12.0
18
11
L04AC07
ATC
tocilizumab; parenteral
129.0
11.6
12
*
L04AB01
ATC
etanercept; parenteral
38.1
11.5
14
*
A02BC02
ATC
pantoprazole; systemic
3.6
10.6
126
815
7143A
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Juvenile chronic polyarthritis[MB STILL]
+∞
10.5
10
*
M01CB01
ATC
sodium aurothiomalate; parenteral
35.1
10.5
13
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.0
9.9
23
52
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
19.0
9.6
14
8
JN6DR
NOMESCO Finland
PET-CT of whole body metabolism
23.4
9.5
13
6
M08.3
ICD-10 Finland
Juvenile polyarthritis (seronegative)
+∞
9.5
9
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.2
9.0
26
70
J01MA12
ATC
levofloxacin; systemic
3.2
8.9
43
165
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.9
8.9
56
250
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
3.8
8.7
30
92
L04AB06
ATC
golimumab; parenteral
94.9
8.5
9
*
A46
ICD-10 Finland
Erysipelas
3.8
8.4
29
89
L04AA11
ATC
[U] etanercept
+∞
8.4
8
*
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
7.6
8.4
19
28
NH3EA
NOMESCO Finland
Feet X-ray examination with load
23.5
8.1
11
5
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
8.0
51
227
TNH11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in ankle joint or foot joint
26.5
7.7
10
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.8
7.6
47
205
L04AA14
ATC
[U] anakinra
+∞
7.3
7
*
208
Kela drug reimbursment
Ulcerative colitis and Crohn's disease
+∞
7.3
7
*
M06.8
ICD-10 Finland
Other specified rheumatoid arthritis
21.2
7.2
10
5
NG1AE
NOMESCO Finland
Knee joint ultrasound exmination
31.6
7.2
9
*
7140A
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Rheumatoid arthritis[ARTHRITIS RHEUMATOIDES SEROPOSITIVA]
31.6
7.2
9
*
NDG30
NOMESCO Finland
Fusion of wrist, total
31.6
7.2
9
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.7
7.2
24
72
TPH04
NOMESCO Finland
Cathetrisation of vein
2.8
7.0
44
193
L04AK01
ATC
leflunomide; oral
41.9
6.8
8
*
D07AC01
ATC
betamethasone; topical
2.4
6.5
68
379
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
15.1
6.5
10
7
K51.9
ICD-10 Finland
Ulcerative colitis, unspecified
72.6
6.5
7
*
J01MA01
ATC
ofloxacin; systemic
4.2
6.5
18
47
M45
ICD-10 Finland
Ankylosing spondylitis
27.9
6.3
8
*
7143C
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Juvenile chronic polyarthritis[POLYARTHRITIS JUVENILIS SERONEGATIVA]
+∞
6.3
6
*
L04AA17
ATC
[U] adalimumab
+∞
6.3
6
*
M06.4
ICD-10 Finland
Inflammatory polyarthropathy
+∞
6.3
6
*
291
Kela drug reimbursment
Tofacitinib
+∞
6.3
6
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
5.5
6.1
17
34
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
25
30
9.70
19.83
1.3
1.4
—
—
—
0
0
32
53
7.31
19.43
1.8
1.5
6.06
6.92
iu/ml
—
8
12
133
718
6.21
19.35
22.7
9.7
4.50
4.00
e9/l
1.32
127
621
24
10
27.98
17.94
4.2
2.3
1339.75
1059.10
u/ml
—
24
10
120
665
4.28
15.08
10.0
2.9
219.69
97.46
ug/l
2.72
114
630
121
718
3.87
12.75
6.4
3.4
0.00
0.00
estimate
-0.00
25
146
121
722
3.83
12.55
6.5
3.5
0.00
0.00
estimate
-0.00
25
136
24
26
10.66
12.52
1.3
1.4
270.67
173.85
u/ml
0.85
18
13
103
566
3.33
12.01
2.8
2.4
75.86
74.66
nmol/l
0.16
98
521
119
717
3.62
11.83
6.5
3.4
0.00
0.00
estimate
-0.00
25
145
52
191
3.56
11.82
2.4
1.9
—
—
—
0
0
43
140
3.84
11.68
2.1
1.6
—
—
—
0
0
39
128
3.71
10.38
2.0
1.7
—
—
—
0
0
91
497
2.94
10.16
6.0
4.1
33.43
36.66
g/l
4.37
86
476
20
24
9.36
9.91
2.2
1.2
—
—
—
0
0
21
29
8.17
9.59
1.2
1.4
142.11
197.88
au/ml
—
9
5
25
63
4.52
9.47
1.8
2.5
40.44
42.45
u/l
0.17
25
55
20
28
8.01
9.07
1.4
1.6
—
—
—
0
0
19
25
8.47
8.95
1.4
1.6
—
—
—
0
0
57
261
2.85
8.57
1.4
1.3
40.50
7.71
u/ml
1.14
23
100
98
591
2.72
8.53
8.9
6.3
1.21
1.22
mmol/l
0.23
88
513
31
100
3.61
8.37
1.5
1.2
124.84
295.16
u/ml
0.54
31
91
19
29
7.29
8.18
1.3
1.2
—
—
—
0
0
16
19
9.23
8.03
1.4
1.7
—
—
—
0
0
13
11
12.74
7.73
1.8
1.6
—
—
—
0
0
18
29
6.86
7.50
1.8
1.7
—
—
—
0
0
16
24
7.28
7.02
1.4
1.7
—
—
—
0
0
12
11
11.68
6.92
2.1
1.5
—
—
—
0
0
57
287
2.54
6.89
1.6
1.3
42.16
31.52
iu/ml
0.34
23
93
17
30
6.21
6.67
1.8
2.0
—
—
—
0
0
18
46
4.28
6.64
1.1
1.3
—
—
—
0
0
15
23
7.08
6.51
1.7
2.2
—
—
—
0
0
88
553
2.32
6.34
7.5
5.6
1.21
1.22
mmol/l
0.73
81
507
69
396
2.31
6.10
6.4
3.5
0.00
0.00
estimate
-0.00
25
134
61
340
2.29
5.71
3.7
2.8
0.24
0.33
e6/l
0.27
50
240
15
28
5.80
5.70
1.7
1.3
0.00
0.00
g/l
-0.00
15
28
9
7
13.52
5.65
1.7
1.4
—
—
—
0
0
54
299
2.22
5.04
3.8
2.0
2.72
2.98
mg/l
0.41
46
257
15
34
4.76
4.89
1.7
1.3
0.00
0.00
g/l
-0.00
15
28
8
7
11.94
4.84
1.8
1.3
—
—
—
0
0
14
30
5.01
4.81
1.4
1.9
—
—
—
0
0
55
317
2.12
4.58
1.6
1.6
—
—
—
0
0
15
45
3.58
4.45
2.9
2.2
—
—
—
0
0
9
12
7.87
4.42
1.3
1.2
—
—
—
0
0
9
12
7.87
4.42
1.3
1.3
—
—
—
0
0
151
1330
3.69
4.38
37.6
12.6
28.43
22.09
mg/l
1.30
142
1046
7
6
12.12
4.31
2.1
1.3
—
—
—
0
0
7
6
12.12
4.31
1.4
1.0
—
—
—
0
0
7
6
12.12
4.31
2.1
3.0
—
—
—
0
0
9
13
7.26
4.22
1.3
1.2
—
—
—
0
0
9
13
7.26
4.22
1.3
1.2
—
—
—
0
0
18
66
2.95
3.90
4.9
2.8
2.48
1.42
mmol/l
0.47
13
56
9
15
6.29
3.87
1.3
1.2
—
—
—
0
0
6
5
12.39
3.79
1.2
1.0
78.50
96.20
%
—
6
5
26
118
2.44
3.76
3.1
3.0
—
—
—
0
0
9
16
5.89
3.71
1.3
1.2
—
—
—
0
0
11
25
4.65
3.70
4.1
2.2
7.53
7.78
kpa
0.20
11
25
15
52
3.08
3.57
1.3
1.5
—
—
—
0
0
71
482
1.85
3.53
4.7
3.4
24.01
26.62
ng/l
0.14
55
301
31
157
2.21
3.50
6.8
4.3
1.07
1.04
mmol/l
0.25
31
143
12
32
3.97
3.47
1.4
1.7
—
—
—
0
0
9
18
5.23
3.42
1.2
1.5
—
—
—
0
0
9
18
5.23
3.42
1.2
1.5
—
—
—
0
0
9
18
5.23
3.42
1.4
1.1
—
—
—
0
0
38
212
2.04
3.35
3.0
2.6
1.25
0.92
e6/l
0.26
21
106
19
79
2.60
3.28
2.2
1.6
—
—
—
0
0
8
15
5.55
3.23
1.4
1.1
—
—
—
0
0
12
37
3.42
3.01
4.3
2.4
24.77
24.82
mmol/l
0.02
12
37
5
5
10.26
3.00
2.2
1.0
—
—
—
0
0
8
17
4.89
2.96
1.0
1.1
—
—
—
0
0
6
9
6.87
2.89
1.2
1.3
—
—
—
0
0
9
23
4.08
2.82
1.8
1.5
—
—
—
0
0
22
106
2.25
2.79
1.2
1.2
41.11
154.29
u/ml
—
7
39
5
6
8.55
2.77
1.4
1.3
—
—
—
0
0
5
6
8.55
2.77
2.2
1.2
—
—
—
0
0
16
67
2.54
2.73
6.8
8.1
25.84
25.61
mmol/l
0.06
16
67
15
61
2.61
2.71
1.9
1.6
—
—
—
0
0
7
15
4.83
2.62
1.0
1.1
—
—
—
0
0
33
191
1.92
2.60
2.9
2.7
2.33
3.43
e6/l
0.39
16
86
5
7
7.33
2.56
1.0
1.9
—
—
—
0
0
124
1050
1.82
2.53
5.0
4.3
14.83
14.58
pmol/l
0.52
115
983
48
318
1.73
2.44
2.8
2.2
—
—
—
0
0
5
8
6.41
2.39
1.4
1.1
459.20
293.00
mg
—
5
8
7
17
4.26
2.39
1.0
2.6
—
—
—
0
0
9
28
3.34
2.34
2.3
1.4
—
—
—
0
0
17
79
2.29
2.34
3.3
3.5
59.92
82.77
ng/l
0.76
17
71
10
34
3.07
2.32
1.6
1.4
—
—
—
0
0
143
1279
2.17
2.32
27.7
12.2
87.20
86.83
ml/min/173m2
0.08
132
1172
74
556
1.62
2.31
6.1
3.1
0.00
0.00
estimate
-0.00
22
124
0
56
0.00
2.11
0.0
1.6
—
38.95
—
0
56
5
10
5.12
2.08
1.0
1.0
—
—
—
0
0
5
10
5.12
2.08
1.0
1.4
—
—
—
0
0
6
15
4.11
2.06
1.0
2.9
—
—
—
0
0
113
961
1.61
1.95
3.5
3.5
—
—
—
0
0
81
641
1.54
1.92
3.1
2.6
—
—
estimate
—
0
0
5
12
4.26
1.83
1.8
1.3
—
9.86
—
0
5
27
164
1.78
1.83
3.2
1.8
28.01
28.96
s
0.55
27
159
34
221
1.68
1.82
2.6
2.7
2.44
2.45
mmol/l
0.20
34
201
9
36
2.59
1.77
1.3
1.2
—
—
—
0
0
8
31
2.66
1.68
3.9
1.2
—
—
—
0
0
5
14
3.65
1.63
1.2
2.0
—
—
—
0
0
5
14
3.65
1.63
1.2
2.0
—
—
—
0
0
5
14
3.65
1.63
1.2
2.0
—
—
—
0
0
137
1243
1.74
1.61
5.9
5.2
1.75
1.84
mu/l
0.42
126
1168
12
58
2.16
1.53
3.1
3.0
24.60
25.04
mmol/l
0.20
12
58
5
15
3.41
1.53
3.6
2.6
106.80
105.00
mmol/l
—
5
15
12
59
2.12
1.48
1.3
2.5
26048.62
801.90
u/l
—
5
22
5
16
3.19
1.45
1.8
1.9
—
—
—
0
0
10
46
2.25
1.43
2.7
2.2
—
—
—
0
0
5
17
3.00
1.37
2.0
1.9
—
—
—
0
0
5
17
3.00
1.37
1.8
1.9
—
—
—
0
0
5
17
3.00
1.37
1.8
1.9
—
—
—
0
0
5
17
3.00
1.37
2.0
1.9
—
—
—
0
0
5
17
3.00
1.37
2.0
1.9
—
—
—
0
0
8
35
2.35
1.29
1.5
1.2
—
—
—
0
0
51
393
1.44
1.28
4.7
3.9
14.30
10.01
mg/mmol
0.27
31
250
33
233
1.53
1.27
4.8
3.1
166.52
305.65
ng/l
0.31
25
165
44
332
1.45
1.23
5.4
2.8
590.81
871.69
ng/l
1.19
38
276
53
415
1.42
1.21
5.6
2.6
0.00
0.00
estimate
-0.00
20
119
14
80
1.82
1.17
1.6
1.4
—
—
—
0
0
24
162
1.57
1.12
2.1
1.6
1127.88
1128.61
nmol/l
0.00
19
122
20
134
1.56
0.97
8.2
7.1
11.17
12.65
kpa
0.98
20
128
20
134
1.56
0.97
8.3
7.1
5.01
5.21
kpa
0.39
20
127
41
320
1.38
0.94
5.8
3.3
1.02
1.02
kg/l
0.10
33
212
9
52
1.77
0.94
2.8
1.5
—
—
—
0
0
11
63
1.80
0.92
1.3
1.3
—
—
—
0
0
8
45
1.82
0.85
2.5
2.0
—
—
—
0
0
124
1150
1.36
0.82
36.5
15.5
14.02
13.46
%
3.99
124
1138
62
528
1.29
0.78
2.5
2.0
92.96
94.75
pmol/l
0.11
40
271
5
29
1.75
0.64
3.0
2.7
3.48
6.26
umol/l
—
5
21
6
105
0.55
0.64
1.7
2.2
—
—
—
0
0
27
212
1.33
0.61
2.2
1.6
460.75
438.43
pmol/l
0.19
20
187
21
161
1.35
0.55
8.5
6.8
104.05
104.40
mmol/l
0.13
21
161
14
100
1.44
0.54
2.0
3.1
63.88
71.50
ml/min/173m2
—
8
40
26
215
1.25
0.41
1.5
2.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
21
257
0.79
0.41
4.0
4.1
20.00
22.82
%
0.40
11
106
140
1356
1.27
0.39
5.6
5.3
2.77
2.81
mmol/l
0.21
130
1284
9
124
0.71
0.36
1.6
2.2
—
—
—
0
0
16
199
0.78
0.36
1.3
2.1
2.97
3.40
ratio
—
9
159
130
1257
1.19
0.32
5.3
5.6
36.84
38.43
mmol/mol
2.03
122
1196
7
52
1.36
0.31
2.1
1.5
—
—
—
0
0
62
573
1.13
0.29
2.2
2.0
1.58
1.39
mmol/l
0.80
50
501
8
66
1.22
0.27
3.9
2.3
1.16
1.37
%
—
8
66
5
37
1.36
0.24
1.2
1.2
—
—
—
0
0
131
1277
1.15
0.22
4.8
4.6
5.55
5.82
mmol/l
3.37
121
1201
0
10
0.00
0.21
0.0
1.3
—
15.40
—
0
10
0
13
0.00
0.21
0.0
1.2
—
222.39
—
0
13
5
67
0.74
0.17
1.0
1.1
1.48
1.58
g/l
—
5
67
5
68
0.73
0.17
1.0
1.2
0.79
0.90
g/l
—
5
68
18
203
0.87
0.16
3.7
2.7
0.53
0.75
ug/l
1.31
12
116
131
1284
1.11
0.16
5.2
4.0
1.32
1.26
mmol/l
0.49
122
1197
6
78
0.76
0.16
1.3
1.0
—
—
—
0
0
39
363
1.10
0.16
1.4
1.3
2.61
1.70
u/ml
—
7
105
11
101
1.10
0.04
14.2
7.1
1.15
1.14
mmol/l
0.02
11
101
27
280
0.96
0.03
1.4
1.5
—
—
—
0
0
135
1342
1.04
0.02
5.3
4.7
1.51
1.48
mmol/l
0.35
126
1268
135
1343
1.03
0.01
5.3
4.8
4.72
4.74
mmol/l
0.11
126
1273
20
194
1.04
0.00
1.6
2.1
—
—
—
0
0
14
139
1.01
0.00
5.9
5.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
14.62
—
0
9
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
4.74
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
62.64
—
0
5
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
7
0.00
-0.00
0.0
2.7
—
112.29
—
0
7
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
5
0.00
-0.00
0.0
1.0
—
128.20
—
0
5
0
5
0.00
-0.00
0.0
3.2
—
11.50
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.4
—
119.20
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint STILL_ADULT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| STILL_ADULT | 1.988 [1.4, 2.83] | < 0.001 |
| Birth year | 0.999 [0.99, 1.01] | 0.737 |
During the follow-up period (1.1.1998 — 31.12.2019), 53 out of 328 females with STILL_ADULT died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| STILL_ADULT | 1.642 [1.18, 2.28] | 0.003 |
| Birth year | 0.988 [0.98, 1.0] | 0.009 |
During the follow-up period (1.1.1998 — 31.12.2019), 57 out of 253 males with STILL_ADULT died.
Mortality risk
Mortality risk for people of age
years, who have STILL_ADULT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.161% | 0.335% |
| 5 | 1.301% | 1.57% |
| 10 | 3.268% | 4.225% |
| 15 | 6.061% | 8.388% |
| 20 | 10.759% | 14.54% |
Relationships between endpoints
↥Index endpoint: STILL_ADULT – Adult-onset Still disease
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data